

DIGIRAD CORP
Form 10-Q
November 02, 2015

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 10-Q

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2015

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE TRANSITION PERIOD FROM _____ TO _____

Commission file number: 000-50789

Digirad Corporation
(Exact name of registrant as specified in its charter)

Delaware
(State or Other Jurisdiction of Incorporation or Organization)

33-0145723
(I.R.S. Employer Identification No.)

1048 Industrial Court, Suwanee, GA
(Address of Principal Executive Offices)
(858) 726-1600

30024
(Zip Code)

(Registrant's Telephone Number, Including Area Code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes No

Indicate by check mark whether registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer Accelerated filer

Non-accelerated filer (Do not check if a smaller reporting company) Smaller reporting company

Indicate by check mark whether registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

As of October 26, 2015 the registrant had 19,416,070 shares of Common Stock (\$0.0001 par value) outstanding.

DIGIRAD CORPORATION
TABLE OF CONTENTS

IMPORTANT INFORMATION REGARDING FOWARD-LOOKING STATEMENTS	3
<u>PART I. FINANCIAL INFORMATION</u>	4
<u>Item 1. Financial Statements</u>	4
<u>Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations</u>	18
<u>Item 3. Quantitative and Qualitative Disclosures about Market Risk</u>	25
<u>Item 4. Controls and Procedures</u>	25
<u>PART II. OTHER INFORMATION</u>	27
<u>Item 1. Legal Proceedings</u>	27
<u>Item 1A. Risk Factors</u>	27
<u>Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</u>	27
<u>Item 3. Defaults Upon Senior Securities</u>	27
<u>Item 4. Mine Safety Disclosures</u>	27
<u>Item 5. Other Information</u>	27
<u>Item 6. Exhibits</u>	28
EXHIBIT 31.1	
EXHIBIT 31.2	
EXHIBIT 32.1	
EXHIBIT 32.2	
EXHIBIT 101.INS XBRL Instance Document	
EXHIBIT 101.SCH XBRL Taxonomy Extension Schema Document	
EXHIBIT 101.CAL XBRL Taxonomy Extension Calculation Linkbase Document	
EXHIBIT 101.LAB XBRL Taxonomy Extension Label Linkbase Document	
EXHIBIT 101.PRE XBRL Taxonomy Extension Presentation Linkbase Document	
EXHIBIT 101.DEF XBRL Taxonomy Extension Definition Linkbase Document	

Important Information Regarding Forward-Looking Statements

Portions of this Quarterly Report on Form 10-Q (including information incorporated by reference) include “forward-looking statements” based on our current beliefs, expectations, and projections regarding our business strategies, market potential, future financial performance, industry, and other matters. This includes, in particular, “Item 2—Management’s Discussion and Analysis of Financial Condition and Results of Operations” of this Quarterly Report on Form 10-Q, as well as other portions of this Quarterly Report on Form 10-Q. The words “believe,” “expect,” “anticipate,” “project,” “could,” “would,” and similar expressions, among others, generally identify forward-looking statements, which speak only as of the date the statements were made. The matters discussed in these forward-looking statements are subject to risks, uncertainties, and other factors that could cause our actual results to differ materially from those projected, anticipated, or implied in the forward-looking statements. The most significant of these risks, uncertainties, and other factors are described in “Item 1A—Risk Factors” of this Quarterly Report on Form 10-Q and in our Annual Report on Form 10-K for the fiscal year ended December 31, 2014 filed with the Securities and Exchange Commission on March 6, 2015. Except to the limited extent required by applicable law, we undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

PART I. FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS
DIGIRAD CORPORATION
CONDENSED CONSOLIDATED STATEMENTS
OF COMPREHENSIVE INCOME
(Unaudited)

(in thousands, except per share data)	Three Months Ended September 30,		Nine Months Ended September 30,	
	2015	2014	2015	2014
Revenues:				
Diagnostic Services	\$ 11,982	\$ 10,821	\$ 34,724	\$ 31,716
Diagnostic Imaging	3,880	3,060	10,525	9,749
Total revenues	15,862	13,881	45,249	41,465
Cost of revenues:				
Diagnostic Services	9,201	8,063	26,920	23,801
Diagnostic Imaging	1,859	1,409	5,112	5,308
Total cost of revenues	11,060	9,472	32,032	29,109
Gross profit	4,802	4,409	13,217	12,356
Operating expenses:				
Marketing and sales	1,212	1,157	3,689	3,497
General and administrative	2,508	2,047	6,880	6,235
Amortization of intangible assets	134	93	372	263
Restructuring charges	—	80	—	659
Total operating expenses	3,854	3,377	10,941	10,654
Income from operations	948	1,032	2,276	1,702
Other income (expense):				
Interest and other income, net	10	14	32	46
Interest expense	(21) (10) (44) (27
Total other income (expense)	(11) 4	(12) 19
Income before income taxes	937	1,036	2,264	1,721
Income tax benefit (expense)	18,183	(8) 18,698	(18
Net income	\$ 19,120	\$ 1,028	\$ 20,962	\$ 1,703
Net income per share:				
Basic	\$ 0.99	\$ 0.06	\$ 1.09	\$ 0.09
Diluted	\$ 0.97	\$ 0.05	\$ 1.07	\$ 0.09
Shares used in per share computations:				
Weighted average shares outstanding – basic	19,356	18,601	19,145	18,558
Weighted average shares outstanding – diluted	19,798	18,895	19,608	18,853
Dividends declared per common share	\$ 0.05	\$ 0.05	\$ 0.15	\$ 0.15

Edgar Filing: DIGIRAD CORP - Form 10-Q

Net income	\$19,120	\$1,028	\$20,962	\$1,703
Other comprehensive income:				
Unrealized gain (loss) on marketable securities	3	(9) 16	(19
Total other comprehensive income (loss)	3	(9) 16	(19
Comprehensive income	\$19,123	\$1,019	\$20,978	\$1,684
See accompanying notes to the unaudited condensed consolidated financial statements				

4

DIGIRAD CORPORATION
 CONDENSED CONSOLIDATED BALANCE SHEETS
 (Unaudited)

(in thousands, except share data)	September 30, 2015	December 31, 2014
Assets		
Current assets:		
Cash and cash equivalents	\$13,895	\$14,051
Securities available-for-sale	5,986	7,935
Accounts receivable, net	8,313	5,989
Inventories, net	4,325	3,644
Other current assets	1,993	856
Restricted cash	233	477
Total current assets	34,745	32,952
Property and equipment, net	6,614	4,766
Intangible assets, net	3,213	2,577
Goodwill	2,897	1,337
Long-term deferred tax assets	16,791	—
Other assets	1,298	269
Total assets	\$65,558	\$41,901
Liabilities and stockholders' equity		
Accounts payable	\$2,797	\$1,423
Accrued compensation	2,872	3,261
Accrued warranty	214	176
Deferred revenue	1,478	1,644
Other accrued liabilities	2,543	1,789
Total current liabilities	9,904	8,293
Other liabilities	1,327	963
Total liabilities	11,231	9,256
Commitments and contingencies (Note 10)		
Stockholders' equity:		
Preferred stock, \$0.0001 par value: 10,000,000 shares authorized; no shares issued or outstanding	—	—
Common stock, \$0.0001 par value: 80,000,000 shares authorized; 19,356,070 and 18,615,945 shares issued and outstanding (net of treasury shares) at September 30, 2015 and December 31, 2014, respectively	2	2
Treasury stock, at cost; 2,588,484 shares at September 30, 2015 and December 31, 2014	(5,728) (5,728
Additional paid-in capital	154,472	153,769
Accumulated other comprehensive loss	(3) (19
Accumulated deficit	(94,416) (115,379
Total stockholders' equity	54,327	32,645
Total liabilities and stockholders' equity	\$65,558	\$41,901
See accompanying notes to the unaudited condensed consolidated financial statements		

DIGIRAD CORPORATION
 CONDENSED CONSOLIDATED STATEMENTS
 OF CASH FLOWS
 (Unaudited)

(in thousands)	Nine Months Ended September 30,	
	2015	2014
Operating activities		
Net income	\$20,962	\$1,703
Adjustments to reconcile net income to net cash provided by operating activities:		
Depreciation	1,379	1,178
Amortization of intangible assets	372	263
Provision for bad debt	162	261
Stock-based compensation	450	207
Loss (gain) on sale of assets	9	(55)
Amortization of premiums on investments	96	154
Deferred income taxes	(18,167))
Changes in operating assets and liabilities:		
Accounts receivable	(2,171)) (1,169)
Inventories	(730)) 406
Other assets	227	(7)
Accounts payable	1,167	1,113
Accrued compensation	(470)) (394)
Deferred revenue	(166)) (208)
Other liabilities	(399)) (240)
Restricted cash	244	(233)
Net cash provided by operating activities	2,965	2,979
Investing activities		
Purchases of property and equipment	(1,181)) (1,147)
Net proceeds from sale of assets	18	81
Purchases of securities available-for-sale	—	(2,617)
Maturities of securities available-for-sale	1,869	1,095
Stock subscription	(1,000))
Net cash received from (paid for) acquisition	3	(3,447)
Net cash used in investing activities	(291)) (6,035)
Financing activities		
Issuances of common stock	432	173
Dividends paid	(2,862)) (2,783)
Repayment of long-term debt	—	(131)
Repayment of obligations under capital leases	(400)) (154)
Net cash used in financing activities	(2,830)) (2,895)
Net decrease in cash and cash equivalents	(156)) (5,951)
Cash and cash equivalents at beginning of period	14,051	18,744
Cash and cash equivalents at end of period	\$13,895	\$12,793

Non-Cash Investing Activities

Edgar Filing: DIGIRAD CORP - Form 10-Q

Assets acquired by entering into capital lease	\$1,340	\$425
Issuances of common stock for acquisition	\$2,684	\$—
See accompanying notes to the unaudited condensed consolidated financial statements		

6

DIGIRAD CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

Note 1. The Company

Digirad Corporation (Digirad), a Delaware corporation, is one of the largest national providers of in-office nuclear cardiology imaging and ultrasound services, and also provides cardiac event monitoring services. These services are provided to physician practices, hospitals, and imaging centers through our Diagnostic Services reportable segment. Digirad also sells solid-state gamma cameras for nuclear cardiology and general nuclear medicine applications, as well as provides service on the products sold, through our Diagnostic Imaging reportable segment. These two reportable segments, Diagnostic Services and Diagnostic Imaging, are collectively referred to herein as the “Company.”

The accompanying condensed consolidated financial statements include the operations of both segments.

Intercompany accounts and transactions are accounted for at cost and have been eliminated in consolidation. All our long-lived assets are located in the United States and substantially all of our revenues arise from sales activity in the United States.

Basis of Presentation

The unaudited condensed consolidated financial statements included in this Form 10-Q have been prepared in accordance with the U.S. Securities and Exchange Commission (SEC) instructions for Quarterly Reports on Form 10-Q. Accordingly, the condensed consolidated financial statements are unaudited and do not contain all the information required by U.S. generally accepted accounting principles (GAAP) to be included in a full set of financial statements. The unaudited condensed consolidated balance sheet at December 31, 2014 has been derived from the audited consolidated financial statements at that date but does not include all of the information and footnotes required by GAAP for a complete set of financial statements. The audited consolidated financial statements for our fiscal year ended December 31, 2014, filed with the SEC on Form 10-K on March 6, 2015, include a summary of our significant accounting policies and should be read in conjunction with this Form 10-Q. In the opinion of management, all material adjustments necessary to present fairly the results of operations, cash flows, and balance sheets for such periods have been included in this Form 10-Q. All such adjustments are of a normal recurring nature. In addition, certain reclassifications have been made to the prior period financial statements to conform to the current period presentation. The results of operations for interim periods are not necessarily indicative of the results of operations for the entire year.

Preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities and the reported amounts of revenues and expenses. By their nature, estimates are subject to an inherent degree of uncertainty. Actual results could differ from management’s estimates.

The financial results for the three and nine months ended September 30, 2015 include the financial results of MD Office Solutions and Telerhythmics, LLC. See Note 3 to the unaudited condensed consolidated financial statements for more information related to the acquisition of MD Office Solutions and Telerhythmics, LLC.

Recent Accounting Pronouncement

In May 2014, the FASB issued guidance that outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers which supersedes most current revenue recognition guidance, including industry-specific guidance. The guidance provides that an entity recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This guidance also requires additional disclosure about the nature, amount, timing, and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments, and assets recognized from costs incurred to obtain or fulfill a contract. The guidance allows for either full retrospective or modified retrospective adoption and is currently scheduled to become effective for us in the first quarter of 2018. We are currently evaluating the alternative transition methods and the potential effects of the adoption of this guidance on our financial statements.

In July 2015, the FASB issued guidance that amends the guidelines for the measurement of inventory from lower of cost or market to the lower of cost and net realizable value (NRV). NRV is defined as the estimated selling prices in

the ordinary course of business less reasonably predictable costs of completion, disposal, and transportation. Under existing standards, inventory is measured at lower of cost or market, which requires the consideration of replacement cost, NRV and NRV less an amount that approximates a normal profit margin. This ASU eliminates the requirement to determine and consider replacement cost or NRV less an approximately normal profit margin for inventory measurement. The new standard is effective prospectively for fiscal years beginning after December 15, 2016. We are currently evaluating the impact, if any, of adopting this guidance on our financial statements.

In September 2015, the FASB issued guidance which eliminates the requirement for an acquirer to retrospectively adjust provisional amounts recorded in a business combination to reflect new information about the facts and circumstances that existed as of the acquisition date and that, if known, would have affected measurement or recognition of amounts initially recognized. As

an alternative, the amendment requires that an acquirer recognize adjustments to provisional amounts that are identified during the measurement period in the reporting period in which the adjustment amounts are determined. The amendments require that the acquirer record, in the financial statements of the period in which adjustments to provisional amounts are determined, the effect on earnings of changes in depreciation, amortization, or other income effects, if any, as a result of the change to the provisional amounts, calculated as if the accounting had been completed at the acquisition date. The new standard is effective prospectively for fiscal years beginning after December 15, 2015, including interim periods within those fiscal years. We are currently evaluating the impact, if any, of adopting this guidance on our financial statements.

We believe that no other new accounting guidance was adopted or issued during 2015 that is relevant to the readers of our financial statements. However, there are numerous new proposals under development which, if and when enacted, may have a significant impact on our financial reporting.

Note 2. Basic and Diluted Net Income Per Share

For the three and nine months ended September 30, 2015 and 2014, basic net income per common share is computed by dividing net income by the weighted average number of common shares and vested restricted stock units outstanding during the period. Diluted net income per common share is calculated to give effect to all dilutive securities, if applicable, using the treasury stock method.

The following table sets forth the reconciliation of shares used to compute basic and diluted net income per share for the periods indicated:

(shares in thousands)	Three Months Ended September 30,		Nine Months Ended September 30,	
	2015	2014	2015	2014
Weighted average shares outstanding - basic	19,356	18,601	19,145	18,558
Dilutive potential common stock outstanding:				
Stock options	418	294	444	295
Restricted stock units	24	—	19	—
Weighted average shares outstanding - diluted	19,798	18,895	19,608	18,853

The following weighted average outstanding common stock equivalents were not included in the calculation of diluted net income per share because their effect was anti-dilutive:

(shares in thousands)	Three Months Ended September 30,		Nine Months Ended September 30,	
	2015	2014	2015	2014
Stock options	1	82	2	85
Restricted stock units	—	—	—	—
Total	1	82	2	85

Note 3. Acquisitions

MD Office Solutions (2015)

On March 5, 2015, we entered into an Agreement of Merger and Plan of Reorganization (the Merger Agreement) to acquire MD Office Solutions (MD Office). MD Office is a provider of in-office nuclear cardiology imaging in the northern and central California regions. The acquisition expands the geographical region in which we are able to provide our in-office nuclear cardiology imaging services.

Total consideration related to the Merger Agreement paid to the sellers was 610,000 shares of common stock of Digirad Corporation, with a total value at closing of \$2,684,000, as well as settlement of a \$15,000 accounts receivable balance owed to the Company. The Company issued new shares for the consideration. In addition, there is an earn-out opportunity of up to \$400,000 in cash over approximately three years based on the MD Office business meeting certain earnings before interest, taxes, depreciation, and amortization (EBITDA) milestones. The sellers will receive fifty percent of the EBITDA generated by the MD Office business in excess of the EBITDA milestone amounts, which are \$650,000 for each of the annual periods ending December 31, 2015, 2016, and 2017, with the target for 2015 being prorated based on the close date.

At September 30, 2015, we have estimated the fair value of the contingent earn-out opportunity to be \$6,000. The earn-out opportunity is estimated based on the expected performance of the business over the period from the acquisition date through December 31, 2017, utilizing an income approach. It is reasonably possible that our estimate of the earn-out potential could change

8

in the near term. Any adjustment in the estimated earn-out opportunity until settled will be recorded as a gain or loss to current operations in the period the estimate changes.

The Merger Agreement was also subject to a post-closing purchase price adjustment based on the final working capital balance, as defined in the Merger Agreement, as well as a Registration Rights Agreement related to the common shares provided to the sellers as part of the consideration.

As of September 30, 2015, the preliminary allocation of the purchase price to the assets acquired and liabilities assumed on the acquisition date was as follows (in thousands):

(in thousands)	Allocation of purchase price
Assets	
Current assets:	
Cash and cash equivalents	\$3
Accounts receivable	457
Other current assets	32
Total current assets	492
Property and equipment	481
Intangible assets	1,007
Goodwill	1,560
Other assets	26
Total assets	\$3,566
Liabilities	
Current liabilities:	
Accounts payable	\$149
Accrued compensation	81
Other accrued liabilities	87
Total current liabilities	317
Deferred tax liability	544
Other liabilities	6
Total liabilities	\$867

The goodwill recognized as part of the transaction primarily represents synergies between Digirad and MD Office that were not separately identified as part of the acquisition valuation process. MD Office activities are included within the Diagnostic Services reportable segment. The resulting goodwill from the acquisition is not deductible for federal and state tax reporting purposes.

The following table summarizes the fair value of acquired identifiable intangible assets as of the acquisition date:

(in thousands)	Weighted Average Useful Lives (in years)	Fair Value
Customer relationships	7.0	\$639
Trademarks	5.0	187
Covenants not to compete	5.0	181
Total intangible assets acquired, excluding goodwill	6.3	\$1,007

As of September 30, 2015, we are continuing to obtain and evaluate certain information related to the assets acquired and liabilities assumed, and therefore the accounting for the acquisition is incomplete. We anticipate closing the measurement period by December 31, 2015.

The below tables display estimated proforma results had the business acquisition been completed as of January 1, 2014. In deriving the proforma results, we utilized the historical operating results of MD Office and adjusted for the impact of the purchase accounting and transaction costs as if the acquisition occurred on January 1, 2014.

(in thousands)	Three Months Ended September 30,		Nine Months Ended September 30,	
	2015	2014	2015	2014
Revenues	\$15,862	\$14,757	\$45,815	\$43,903
Net income	\$19,127	\$1,052	\$21,172	\$1,533

Included within our consolidated operating results for the three and nine months ended September 30, 2015 are MD Office operations for the period March 6, 2015 through September 30, 2015 as follows:

(in thousands)	Three Months Ended September 30, 2015	Nine Months Ended September 30, 2015
Revenues	\$776	\$1,757
Net income	\$151	\$74

Included within the results for MD Office for the nine months ended September 30, 2015 is approximately \$195,000 of transaction costs related to the acquisition. These costs are classified as general and administrative expenses in the consolidated statements of comprehensive income.

Telerhythmics, LLC (2014)

On March 13, 2014, we acquired 100% of the membership interest of Telerhythmics, LLC (Telerhythmics), a provider of 24 hour cardiac monitoring services. We paid to the sellers of the membership interest (the Sellers) aggregate up front consideration of \$3.4 million and assumed approximately \$131,000 in debt. In addition, there is an aggregate earn-out opportunity of up to \$501,000 from the period March 14, 2014 through December 31, 2016 based on the Telerhythmics business meeting certain earnings before interest, taxes, depreciation and amortization (EBITDA) milestones. The Sellers will receive fifty percent (50%) of the EBITDA generated by the Telerhythmics business in excess of the EBITDA milestone amounts, which are as follows:

\$415,000 of EBITDA for the period from the closing date through December 31, 2014,

\$825,000 of EBITDA for the period from January 1, 2015 through December 31, 2015; and

\$825,000 of EBITDA for the period from January 1, 2016 through December 31, 2016.

At September 30, 2015, we have estimated the fair value of the contingent earn-out opportunity to be \$56,000. The earn-out opportunity is estimated based on the expected performance of the business over the period from January 1, 2015 through December 31, 2016, utilizing an income approach. No earn-out consideration was earned by the Sellers for the period from the closing date through December 31, 2014. It is reasonably possible that our estimate of the earn-out potential could change in the near term. Any adjustment in the estimated earn-out opportunity until settled will be recorded as a gain or loss to current operations in the period the estimate changes. During the nine months ended September 30, 2015, the estimate of the fair value of the contingent consideration related to the Telerhythmics acquisition was reduced by \$173,000. The resulting gain was recognized as a reduction of general and administrative operating expense.

The allocation of the purchase price to the assets acquired and liabilities assumed on the acquisition date was as follows:

	Allocation of purchase price
Assets	
Current assets:	
Accounts receivable	\$256
Other current assets	34
Total current assets	290
Property and equipment	290
Intangible assets	2,580
Goodwill	1,153
Total assets	\$4,313
Accounts payable	\$36
Accrued compensation	169
Other accrued liabilities	356
Current portion of long-term debt	131
Total current liabilities	692
Other liabilities	174
Total liabilities	\$866

The long-term debt was subsequently paid in full on March 28, 2014.

The goodwill recognized as part of the transaction primarily represents synergies between Digirad and Telerhythmics that were not separately identified as part of the acquisition valuation process. Telerhythmics activities are considered their own operating segment, which is aggregated into our Diagnostic Services reportable segment. The resulting goodwill from the acquisition is expected to be deductible for federal and state tax reporting purposes.

The below tables display estimated proforma results had the business acquisition been completed as of January 1, 2013. In deriving the proforma results, we utilized the historical operating results of Telerhythmics and adjusted for the impact of the purchase accounting and transaction costs as if the acquisition occurred on January 1, 2013.

(in thousands)	Three Months Ended September 30,		Nine Months Ended September 30,	
	2014	2013	2014	2013
Revenues	\$13,881	\$13,988	\$42,620	\$41,402
Net income (loss)	\$1,041	\$2,555	\$1,903	\$(543)

Note 4. Inventories

Our inventories are stated at the lower of cost (first-in, first-out) or market (net realizable value) and we review inventory balances for excess and obsolete inventory levels on a quarterly basis.

(in thousands)	September 30, 2015	December 31, 2014
Inventories:		
Raw materials	\$3,096	\$2,439
Work-in-process	1,127	2,560
Finished goods	1,257	558
Total inventories	5,480	5,557
Less reserve for excess and obsolete inventories	(1,155)	(1,913)
Total inventories, net	\$4,325	\$3,644

Note 5. Property and Equipment

(in thousands)	September 30, 2015	December 31, 2014
Property and equipment:		
Machinery and equipment	\$25,323	\$23,412
Computer hardware and software	3,472	2,917
Leasehold improvements	583	571
Total property and equipment	29,378	26,900
Less accumulated depreciation	(22,764)	(22,134)
Total property and equipment, net	\$6,614	\$4,766

(in thousands)	September 30, 2015			
	Weighted Average Useful Life (years)	Gross Carrying Amount	Accumulated Amortization	Intangible Assets, Net (1)
Intangible assets with indefinite useful lives:				
Goodwill ⁽²⁾	Indefinite	\$2,897	\$—	\$2,897
Intangible assets with finite useful lives:				
Customer relationships ⁽²⁾	8.2	\$5,489	\$(3,166)	\$2,323
Trademarks ⁽²⁾	8.0	787	(124)	663
Patents	14.1	141	(123)	18
Covenants not to compete ⁽²⁾	5.0	251	(42)	209
Total intangible assets, net		\$6,668	\$(3,455)	\$3,213

	December 31, 2014			
	Weighted Average Useful Life (years)	Gross Carrying Amount	Accumulated Amortization	Intangible Assets, Net (1)
Intangible assets with infinite useful lives:				
Goodwill	Indefinite	\$1,337	\$—	\$1,337
Intangible assets with finite useful lives:				
Customer relationships	8.6	\$4,850	\$(2,904)	\$1,946
Trademarks	9.0	600	(53)	547
Patents	13.2	141	(116)	25
Covenants not to compete	5.0	70	(11)	59
Total intangible assets, net		\$5,661	\$(3,084)	\$2,577

Amortization expense for intangible assets, net was \$0.4 million and \$0.3 million for the nine months ended

(1) September 30, 2015 and 2014, respectively. Estimated amortization expense for intangible assets for the remainder of 2015 is \$0.1 million, for 2016 is \$0.5 million, for 2017 is \$0.5 million, for 2018 is \$0.5 million, for 2019 is \$0.4 million, for 2020 is \$0.4 million, and thereafter is \$0.8 million.

(2) As a result of our acquisition of MD Office on March 5, 2015, we recorded certain intangible assets (See Note 3).

Note 7. Restructuring Charges

Facilities restructuring initiative

On January 27, 2014, we announced a plan to exit our 47,000 square foot former headquarters facility in Poway, California (the Facilities restructuring initiative). This action was undertaken as the facility had excess space and capacity given our current operating plan. We entered into a termination agreement to end the lease on the facility as of April 30, 2014. The original term of the lease

would have continued through February 29, 2016. Concurrently with the termination of the lease for the 47,000 square foot Poway, California facility, we entered into a new lease agreement on January 23, 2014 for a separate 21,300 square foot facility in Poway, California to house our Diagnostic Imaging operations.

As a result of the Facilities restructuring initiative, we incurred a total of \$0.7 million in restructuring charges which occurred solely during fiscal year 2014. Facilities restructuring charges of \$0.1 million and \$0.6 million were incurred during the three and nine months ended September 30, 2014, respectively. No Facilities restructuring charges were incurred during the three or nine months ended September 30, 2015. The charges were comprised of lease termination, moving, and other related costs. All Facilities restructuring charges were included in the Diagnostic Imaging segment. Restructuring liabilities and associated charges were measured at fair value as incurred.

Note 8. Financial Instruments

Assets and Liabilities Measured at Fair Value on a Recurring Basis. The following table presents information about our financial assets and liabilities that are measured at fair value on a recurring basis, and indicates the fair value hierarchy of the valuation techniques we utilize to determine such fair value at September 30, 2015 and December 31, 2014.

(in thousands)	Fair Value as of September 30, 2015			Total
	Level 1	Level 2	Level 3	
Assets:				
Corporate debt securities	\$—	\$5,986	\$—	\$5,986
Liabilities:				
Acquisition related contingent consideration	\$—	\$—	\$62	\$62

(in thousands)	Fair Value as of December 31, 2014			Total
	Level 1	Level 2	Level 3	
Assets:				
Corporate debt securities	\$—	\$7,935	\$—	\$7,935
Liabilities:				
Acquisition related contingent consideration	\$—	\$—	\$229	\$229

The fair value of our corporate debt securities is determined using proprietary valuation models and analytical tools. These valuation models and analytical tools use market pricing or prices for similar instruments that are both objective and publicly available, including matrix pricing or reported trades, benchmark yields, broker/dealer quotes, issuer spreads, two-sided markets, benchmark securities, bids, and/or offers. We did not reclassify any investments between levels in the fair value hierarchy during the nine months ended September 30, 2015.

The acquisition related contingent consideration is related to our acquisition of Telerhythmics on March 13, 2014 and acquisition of MD Office on March 5, 2015 (See Note 3). We reassess the fair value of the contingent consideration to be settled in cash related to our acquisitions of Telerhythmics and MD Office on a quarterly basis using the income approach, which is a Level 3 measurement. During the nine months ended September 30, 2015, \$6,000 of contingent consideration was established related to the MD Office acquisition, and the contingent consideration related to the Telerhythmics acquisition was reduced by \$173,000. The resulting gain related to the reduction of the Telerhythmics acquisition contingent consideration was recognized as a reduction of general and administrative operating expense. Significant assumptions used in the measurement include probabilities of achieving the EBITDA milestones and estimated future earnings.

Securities Available for Sale

Securities available-for-sale primarily consist of investment grade corporate debt securities. We classify all securities as available-for-sale and as current assets, as the sale of such securities may be required prior to maturity to execute management strategies. These securities are carried at fair value, with the unrealized gains and losses reported as a component of accumulated other comprehensive income (loss) in stockholders' equity until realized. Realized gains and losses from the sale of available-for-sale securities, if any, are determined on a specific identification basis. A decline in the market value of any available-for-sale security below cost that is determined to be other than temporary will result in an impairment charge to earnings and a new cost basis for the security is established. No such

impairment charges were recorded for any period presented. It is not more likely than not that we will be required to sell investments before recovery of their amortized costs. Premiums and discounts are amortized or accreted over the life of the related security as an adjustment to yield using the straight-line method and included in interest income. Interest income is recognized when earned. Realized gains and losses on investments in securities are included in other income (expense) within the condensed consolidated statements of comprehensive income. The realized gains and losses on these sales were minimal for the three and nine months ended September 30, 2015 and 2014.

The following table sets forth the composition of securities available-for-sale as of September 30, 2015 and December 31, 2014.

As of September 30, 2015 (in thousands)	Maturity in Years	Amortized Cost	Unrealized		Fair Value
			Gains	Losses	
Corporate debt securities	Less than 1 year	\$ 4,658	\$ 1	\$(2)) \$4,657
Corporate debt securities	1-3 years	1,331	—	(2)) 1,329
		\$ 5,989	\$ 1	\$(4)) \$5,986

As of December 31, 2014 (in thousands)	Maturity in Years	Amortized Cost	Unrealized		Fair Value
			Gains	Losses	
Corporate debt securities	Less than 1 year	\$ 4,650	\$—	\$(5)) \$4,645
Corporate debt securities	1-3 years	3,304	—	(14)) 3,290
		\$ 7,954	\$—	\$(19)) \$7,935

Note 9. Perma-Fix Medical Stock Subscription and Supply Agreements

On July 27, 2015, we entered into a Stock Subscription Agreement (the Subscription Agreement) and Tc-99m Supplier Agreement (the Supply Agreement) with Perma-Fix Medical, S.A. (Perma-Fix Medical), a publicly traded company listed on the NewConnect market of the Warsaw Stock Exchange. Perma-Fix Medical is a subsidiary of Perma-Fix Environmental Services, Inc. (NASDAQ: PESI). Perma-Fix Medical is developing a proprietary process to produce Technetium-99m (Tc-99m) resin from non-enriched uranium sources for purposes of creating nuclear imaging isotopes. Under the terms of the Subscription Agreement, we invested \$1 million USD in exchange for 71,429 shares of Perma-Fix Medical, which constitutes approximately 5.4% of the outstanding common shares of Perma-Fix Medical at the time of investment. Under Polish law, issuance of the shares required approval of the shares by a Polish court which occurred on October 12, 2015. As approval and issuance of the shares had not occurred as of September 30, 2015, the funds provided related to the subscription agreement are included in Other assets in the unaudited condensed consolidated balance sheet as of September 30, 2015. In connection with the Subscription Agreement, the Company's President and CEO was appointed to the Supervisory Board of Perma-Fix Medical. See Note 13 to the unaudited condensed consolidated financial statements for further information regarding Perma-Fix Medical and Perma-Fix Environmental Services, Inc.

Pursuant to the Supply Agreement, should Perma-Fix Medical successfully complete development of the new Tc-99m resin, Perma-Fix Medical will supply us or our preferred nuclear pharmacy supplier with Tc-99m at a preferred rate and we will purchase agreed upon quantities of such Tc-99m for our nuclear imaging operations, either directly or in conjunction with our preferred nuclear pharmacy supplier.

Note 10. Commitments and Contingencies

In the normal course of business, we have been, and will likely continue to be, subject to litigation or administrative proceedings incidental to our business, such as claims related to customer disputes, employment practices, wage and hour disputes, product liability, professional liability, commercial disputes, licensure restrictions or denials, and warranty or patent infringement. Responding to litigation or administrative proceedings, regardless of whether they have merit, can be expensive and disruptive to normal business operations. We are not able to predict the timing or outcome of these matters.

Note 11. Income Taxes

We provide for income taxes under the liability method. This approach requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of differences between the tax basis of assets or liabilities and their carrying amounts in the financial statements. We provide a valuation allowance for deferred tax assets if it is more likely than not that these items will expire before we are able to realize their benefit. We calculate the valuation allowance in accordance with the authoritative guidance relating to income taxes, which requires an assessment of

both positive and negative evidence regarding the realizability of these deferred tax assets when measuring the need for a valuation allowance. Significant judgment is required in determining any valuation allowance against deferred tax assets. As of December 31, 2014, due to a history of operating losses and other key operating factors, we concluded that a full valuation allowance was necessary to offset all of our deferred tax assets. A significant piece of objective negative evidence evaluated as of December 31, 2014, was the cumulative pretax loss incurred over the three-year period ended December 31, 2014. As of September 30, 2015, we concluded that it was more likely than not that a portion of our deferred tax assets would be realized through future taxable income. This conclusion was based on our restructuring efforts

in 2013 and 2014 and resulting sustained profitability for the second half of 2013, 2014 and the nine months ended September 30, 2015, as well as our projections of positive future earnings and other key operating factors. As of September 30, 2015, we had generated cumulative pretax income over the preceding twelve quarter period, and therefore the objective negative evidence of a history of operating losses was no longer present. Of the \$35.0 million of deferred tax assets as of September 30, 2015, available evidence supported the realization of \$18.1 million of those assets. The release of the associated valuation allowance resulted in an income tax benefit of \$18.2 million, which was recorded as a discrete item in the three months ended September 30, 2015. The release of the valuation allowance will not affect the amount of cash paid for income taxes.

We will reassess the ability to realize the deferred tax assets on a quarterly basis. If it is more likely than not that we will not realize the recognized deferred tax assets, then all or a portion of the valuation allowance may need to be re-established, which would result in a charge to tax expense. Conversely, if new events indicate that it is more likely than not that we will realize additional deferred tax assets, then all or a portion of the remaining valuation allowance may be released, which would result in a tax benefit.

Further, during the nine months ended September 30, 2015, we recorded an income tax benefit of approximately \$0.5 million related to the release of valuation allowance associated with the acquisition of MD Office. The valuation allowance release occurred when we recorded an increase to our deferred tax liability balance as a result of book and tax basis differences in acquired fixed, intangible, and other assets of MD Office.

As of September 30, 2015, we had unrecognized tax benefits of approximately \$3.9 million related to uncertain tax positions. Included in the unrecognized tax benefits were \$3.2 million of tax benefits that, if recognized, would reduce our annual effective tax rate, subject to the valuation allowance.

We file income tax returns in the U.S. and in various state jurisdictions with varying statutes of limitations. We are no longer subject to income tax examination by tax authorities for years prior to 2009; however, our net operating loss and research credit carry-forwards arising prior to that year are subject to adjustment. It is our policy to recognize interest expense and penalties related to income tax matters as a component of income tax expense.

Note 12. Segments

Our reporting segments have been determined based on the nature of the products and/or services offered to customers or the nature of their function in the organization. We evaluate performance based on the operating income (loss) contributed by each segment.

(in thousands)	Three Months Ended September 30,		Nine Months Ended September 30,	
	2015	2014	2015	2014
Gross profit by segment:				
Diagnostic Services	\$2,781	\$2,758	\$7,804	\$7,915
Diagnostic Imaging	2,021	1,651	5,413	4,441
Condensed consolidated gross profit	\$4,802	\$4,409	\$13,217	\$12,356
Income (loss) from operations by segment:				
Diagnostic Services	\$14	\$167	\$(116)	\$275
Diagnostic Imaging ⁽¹⁾	934	865	2,392	1,427
Condensed consolidated income from operations	\$948	\$1,032	\$2,276	\$1,702
Depreciation and amortization:				
Diagnostic Services	\$591	\$442	\$1,534	\$1,248
Diagnostic Imaging	74	55	217	193
Condensed consolidated depreciation and amortization	\$665	\$497	\$1,751	\$1,441
(in thousands)			September 30, 2015	December 31, 2014
Identifiable assets by segment:				
Diagnostic Services			\$22,657	\$18,724
Diagnostic Imaging			42,901	23,177
Condensed Consolidated assets			\$65,558	\$41,901

⁽¹⁾ Included in the Diagnostic Imaging income from operations for the three and nine months ended September 30, 2014, are approximately \$0.1 million and \$0.7 million of charges, respectively, associated with our Facilities restructuring initiative (See Note 7).

Note 13. Related Party Transaction

Mr. John Climaco currently serves as a Director of the Company and a member of the Audit, Compensation, Corporate Governance and Strategic Advisory committees of the Board. Mr. Climaco also serves as a Director of Perma-Fix Environmental Services, Inc. (NASDAQ: PESI). Further, On June 2, 2015, Mr. Climaco was elected as the Executive Vice President of Perma-Fix Medical S.A., a majority-owned Polish subsidiary of Perma-Fix Environmental Services, Inc. As described in Note 9 to the unaudited condensed consolidated financial statements, on July 27, 2015, we entered into a Stock Subscription Agreement (the Subscription Agreement) and Tc-99m Supplier Agreement (the Supply Agreement) with Perma-Fix Medical. Under the terms of the Subscription Agreement, we invested \$1 million USD in exchange for 71,429 shares of Perma-Fix Medical. Pursuant to the Supply Agreement, should Perma-Fix Medical successfully complete development of the new Tc-99m resin, Perma-Fix Medical will supply us or our preferred nuclear pharmacy supplier with Tc-99m at a preferred rate and we will purchase agreed upon quantities of such Tc-99m for our nuclear imaging operations, either directly or in conjunction with our preferred nuclear pharmacy supplier. In addition, in connection with the Subscription Agreement, the Company's President and CEO was appointed to the Supervisory Board of Perma-Fix Medical.

Note 14. Subsequent Events

Stock Purchase Agreement

On October 13, 2015, we entered into a Stock Purchase Agreement (the Purchase Agreement) with Project Rendezvous Holding Corporation (PRHC) and the stockholders of PRHC named therein (collectively, Stockholders) and Platinum Equity Advisors, LLC as the Stockholder representative (the Stockholder Representative), pursuant to which, subject to the satisfaction or waiver of certain conditions, we will purchase from the Stockholders all of the issued and outstanding common stock of PRHC

(the Transaction). Upon closing of the Transaction, PRHC would be a wholly owned subsidiary of the Company. PRHC is the parent of DMS Health Technologies, Inc. (DMS Health), a provider of mobile diagnostic imaging and related sales and services to small and regional hospitals throughout the United States, with a large concentration in the upper Midwest region.

The purchase price for the contemplated Transaction is \$36 million in cash (the Purchase Price), subject to certain adjustments. We expect to fund payment of the Purchase Price with a combination of cash-on-hand and the committed financing described below.

The completion of the Transaction is subject to customary closing conditions. The Transaction is not subject to approval by the Company's stockholders. The Purchase Agreement contains representations, warranties and covenants of PRHC, the Stockholders and Digirad that are customary for a transaction of this nature. The Purchase Agreement also contains indemnification obligations of the parties thereto. Assuming the satisfaction or waiver of the closing conditions, the Transaction is expected to close by December 31, 2015. The Purchase Agreement provides Digirad and PRHC with certain termination rights, including if the closing of the Transaction has not occurred by January 15, 2016, or such later date as mutually agreed to in writing by Digirad and PRHC.

Committed Financing

In connection with the Transaction, we entered into a commitment letter, dated as of October 13, 2015 (the Commitment Letter), with Wells Fargo Bank, National Association (Wells Fargo) pursuant to which Wells Fargo committed, on the terms and conditions set forth in the Commitment Letter (the Commitments), to provide the Company with a senior secured credit facility in the aggregate amount of \$40 million (the Credit Facility). The Commitments under the Commitment Letter are subject to various conditions, including consummation of the Transaction. In the event the initial funding under the Credit Facility does not occur on or prior to January 15, 2016, then Wells Fargo's commitment to provide the Credit Facility will automatically expire on such date.

Dividend

On October 30, 2015, the Company announced a cash dividend of \$0.05 per share payable on November 27, 2015 to shareholders of record on November 16, 2015.

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

This management's discussion and analysis of financial condition and results of operations (MD&A), contains forward-looking statements that involve risks and uncertainties. Please see "Important Information Regarding Forward-Looking Statements" for a discussion of the uncertainties, risks, and assumptions that may cause our actual results to differ materially from those discussed in the forward-looking statements. This discussion should be read in conjunction with our unaudited condensed consolidated financial statements and related notes thereto and the other disclosures contained elsewhere in this Quarterly Report on Form 10-Q, and the audited consolidated financial statements and related notes thereto for the fiscal year ended December 31, 2014, which were included in our Form 10-K, filed with the U.S. Securities and Exchange Commission (SEC) on March 6, 2015.

The results of operations for the periods reflected herein are not necessarily indicative of results that may be expected for future periods.

Overview

We are one of the largest national providers of in-office nuclear cardiology imaging and ultrasound services, and also provide cardiac event monitoring services. Our services are provided to physician practices, hospitals, and imaging centers through our Diagnostic Services reportable segment. We also sell solid-state gamma cameras for nuclear cardiology and general nuclear medicine applications, as well as provide service on the products we sell through our Diagnostic Imaging reportable segment. We designed and commercialized the first solid-state nuclear gamma camera for the detection of cardiovascular disease and other medical conditions. Our imaging systems are sold in both portable and fixed configurations, and provide enhanced operability and improved patient comfort. Our nuclear cameras fit easily into floor spaces as small as seven feet by eight feet, and facilitate the delivery of nuclear medicine procedures in a physician's office, an outpatient hospital setting, or within multiple departments of a hospital, (e.g., emergency and operating rooms).

Through Diagnostic Services, we offer a convenient and economically efficient imaging services program as an alternative to purchasing a gamma camera or ultrasound equipment or outsourcing the procedures to another physician or imaging center. For physicians who wish to perform nuclear imaging, echocardiography, vascular or general ultrasound tests, or any combination of these procedures in their offices, we provide the ability for them to engage our services, which includes the use of our imaging system, qualified personnel, and related items required to perform imaging in their own offices and bill Medicare, Medicaid, or one of the third-party healthcare insurers directly for those services. The flexibility of our products and our service allows physicians to ensure continuity of care and convenience for their patients and allows them to retain revenue from procedures they would otherwise refer to imaging centers and hospitals. The imaging services are primarily provided to cardiologists, internal medicine physicians, and family practice doctors who enter into annual contracts for a set number of days ranging from once per month to five times per week. We experience some seasonality related to vacations, holidays, and inclement weather. Most of the imaging services are focused on cardiac care. Many of our physician customers are reliant on reimbursements from Medicare, Medicaid, and third-party insurers where, in the past, there has been downward price pressure and uncertainty of reimbursement rates due to factors outside the physicians' control. The uncertainty created by the 2010 healthcare reform laws and other legislation has impacted our business in the past, and will likely have some impact on our business in the future. Future changes and related impacts may require modifications to our current business model in order for our physician customers and us to maintain a viable economic model.

With the acquisition of Telerhythmics, LLC on March 13, 2014, we broadened our suite of service offerings provided through the Diagnostic Services segment, enabling the provision of outsourced cardiac event monitoring services. Providing these services offers flexibility and convenience to our customers who do not have to incur the costs of staffing, equipment, and logistics to monitor patients as part of their standard of care. Our cardiac event monitoring services are provided primarily through an independent diagnostic testing facility model which allows us to bill Medicare, Medicaid, or one of the third-party healthcare insurers directly for services provided. As such, our cardiac event monitoring services are directly subject to reimbursements from Medicare, Medicaid, and third-party insurers which are subject to change on a periodic basis. Our cardiac event monitoring services are mainly provided to physician practices and hospitals.

Our Diagnostic Imaging segment revenue results primarily from selling solid-state gamma cameras and camera maintenance contracts. We sell our imaging systems to physician offices and hospitals primarily in the United States, although we have sold a small number of imaging systems internationally.

For many years since our Initial Public Offering in 2004, we focused significant efforts on research and development activities to develop and further enhance our nuclear imaging cameras, primarily for alternative uses within the healthcare environment. These efforts, along with a fixed infrastructure that was sized for a much higher volume of manufacturing and sales of our nuclear imaging cameras than we have experienced, resulted in several years of financial losses. On February 28, 2013, we announced a plan to restructure our Diagnostic Imaging business to significantly reduce costs and improve profitability (the Diagnostic Imaging restructuring initiative). The Diagnostic Imaging restructuring initiative involved a reduction in force focused on manufacturing, research and development, and administrative personnel. In addition, we entered into an agreement in September 2013 with a third

party to outsource the majority of the manufacturing associated with our cameras. All restructuring efforts associated with this initiative were complete as of June 30, 2014. Further, on January 27, 2014, we entered into a termination agreement to end the lease on our 47,000 square foot former headquarters facility in Poway, California (the Facilities restructuring initiative) and moved our Diagnostic Imaging operations into a separate 21,300 square foot facility. All restructuring efforts associated with the Facilities restructuring initiative were complete as of December 31, 2014. With these restructuring initiatives complete, we plan to continue selling and servicing our cameras, but at a more profitable level with our restructured, leaner infrastructure. We believe that our cameras have underlying technology and related patents that make them relevant into the future.

Our main strategic focus moving forward is on growing our Diagnostic Services business, which we plan to accomplish by driving revenue density with our existing customers by providing additional service offerings, such as cardiac event monitoring, as well as by increasing our overall number of customers through territory expansion and acquisition of other diagnostic services companies. On March 5, 2015, we acquired MD Office Solutions, a provider of in-office nuclear cardiology imaging in the northern and central California regions. On October 13, 2015, we entered into a Stock Purchase Agreement, subject to the satisfaction or waiver of certain conditions, to purchase DMS Health, a provider of mobile diagnostic imaging and related sales and services to small and regional hospitals throughout the United States, with a large concentration in the upper Midwest region. We will also continue to evaluate acquisition opportunities related to complementary healthcare services and products to diversify and expand our current offerings.

Critical Accounting Policies and Estimates

In preparing our financial statements, we make estimates, assumptions, and judgments that can have a significant impact on our revenue and net income or loss, as well as on the value of certain assets and liabilities on our balance sheet. We believe that the estimates, assumptions, and judgments involved in the accounting policies described in Management's Discussion and Analysis of Financial Condition and Results of Operations in Item 7 of our Annual Report on Form 10-K for the fiscal year ended December 31, 2014 have the greatest potential impact on our financial statements, so we consider them to be our critical accounting policies and estimates. We believe that there were no significant changes in those critical accounting policies and estimates during the nine months ended September 30, 2015.

Results of Operations

The following tables set forth our results from operations for the three and nine months ended September 30, 2015 and 2014:

Edgar Filing: DIGIRAD CORP - Form 10-Q

(in thousands)	Three Months Ended September 30,							
	2015	Percent of 2015 Revenues	2014	Percent of 2014 Revenues	Change from Prior Year			
					Dollars	Percent		
Revenues:								
Diagnostic Services	\$11,982	75.5	% \$10,821	78.0	% \$1,161	10.7		%
Diagnostic Imaging	3,880	24.5	% 3,060	22.0	% 820	26.8		%
Total revenues	15,862	100	% 13,881	100	% 1,981	14.3		%
Cost of revenues:								
Diagnostic Services	9,201	58.0	% 8,063	58.1	% 1,138	14.1		%
Diagnostic Imaging	1,859	11.7	% 1,409	10.2	% 450	31.9		%
Total cost of revenues	11,060	69.7	% 9,472	68.2	% 1,588	16.8		%
Gross profit	4,802	30.3	% 4,409	31.8	% 393	8.9		%
Diagnostic Services gross profit percentage	23.2	%	25.5	%		(2.3))%
Diagnostic Imaging gross profit percentage	52.1	%	54.0	%		(1.9))%
Operating expenses:								
Marketing and sales	1,212	7.6	% 1,157	8.3	% 55	4.8		%
General and administrative	2,508	15.8	% 2,047	14.7	% 461	22.5		%
Amortization of intangible assets	134	0.8	% 93	0.7	% 41	44.1		%
Restructuring charges	—	—	% 80	0.6	% (80)	(100.0))%
Total operating expenses	3,854	24.3	% 3,377	24.3	% 477	14.1		%
Income from operations	948	6.0	% 1,032	7.4	% (84)	(8.1))%
Total other income (loss)	(11)	(0.1))% 4	—	% (15)	(375.0))%
Income before income taxes	937	5.9	% 1,036	7.5	% (99)	(9.6))%
Income tax benefit (expense)	18,183	114.6	% (8)	(0.1))% 18,191	(227,388))%
Net income	\$19,120	120.5	% \$1,028	7.4	% \$18,092	1,759.9		%

Edgar Filing: DIGIRAD CORP - Form 10-Q

(in thousands)	Nine Months Ended September 30,				Change from Prior Year			
	2015	Percent of 2015 Revenues	2014	Percent of 2014 Revenues	Dollars	Percent		
Revenues:								
Diagnostic Services	\$34,724	76.7	% \$31,716	76.5	% \$3,008	9.5	%	
Diagnostic Imaging	10,525	23.3	% 9,749	23.5	% 776	8.0	%	
Total revenues	45,249	100	% 41,465	100	% 3,784	9.1	%	
Cost of revenues:								
Diagnostic Services	26,920	59.5	% 23,801	57.4	% 3,119	13.1	%	
Diagnostic Imaging	5,112	11.3	% 5,308	12.8	% (196)	(3.7))%	
Total cost of revenues	32,032	70.8	% 29,109	70.2	% 2,923	10.0	%	
Gross profit	13,217	29.2	% 12,356	29.8	% 861	7.0	%	
Diagnostic Services gross profit percentage	22.5	%	25.0	%		(2.5))%	
Diagnostic Imaging gross profit percentage	51.4	%	45.6	%		5.8	%	
Operating expenses:								
Marketing and sales	3,689	8.2	% 3,497	8.4	% 192	5.5	%	
General and administrative	6,880	15.2	% 6,235	15.0	% 645	10.3	%	
Amortization of intangible assets	372	0.8	% 263	0.6	% 109	41.4	%	
Restructuring charges	—	—	% 659	1.6	% (659)	(100.0))%	
Total operating expenses	10,941	24.2	% 10,654	25.7	% 287	2.7	%	
Income from operations	2,276	5.0	% \$1,702	4.1	% 574	33.7	%	
Total other income (loss)	(12)	—	% 19	—	% (31)	(163.2))%	
Income before income taxes	2,264	5.0	% 1,721	4.2	% 543	31.6	%	
Income tax benefit (expense)	18,698	41.3	% (18)	—	% 18,716	(103,978))%	
Net income	\$20,962	46.3	% \$1,703	4.1	% \$19,259	1,130.9	%	

Comparison of the Three Months Ended September 30, 2015 and 2014

Revenues

Consolidated. Consolidated revenue was \$15.9 million for the three months ended September 30, 2015, an increase of \$2.0 million, or 14.3%, compared to the prior year quarter, due to an increase in revenue in both our Diagnostic Services and Diagnostic Imaging businesses. Our Diagnostic Services business benefited from \$0.8 million of incremental revenue associated with the MD Office acquisition, which occurred on March 5, 2015. The remainder of the increase in Diagnostic Services revenue is associated with a \$0.4 million increase in cardiac monitoring revenue during the three months ended September 30, 2015 as compared to the prior year quarter. Diagnostic Imaging revenue increased \$0.8 million compared to the prior year quarter due to an increase in the number of cameras sold during the three months ended September 30, 2015 as compared to the prior year quarter, offset partially by attrition in the number of associated camera maintenance contracts. Diagnostic Services revenue accounted for 75.5% of total revenues for the three months ended September 30, 2015, compared to 78.0% for the prior year quarter. The percentage of consolidated revenue associated with our Diagnostic Imaging segment was higher for the three months ended September 30, 2015 compared to the prior year quarter, primarily due to the greater volume of cameras sold quarter over quarter. We expect our Diagnostic Services revenue to continue to represent the larger percentage of our consolidated revenue, however the percentage will fluctuate quarter by quarter given the significant variability in the timing and volume of camera unit sales.

Cost of Revenue and Gross Profit

Consolidated. Consolidated gross profit was \$4.8 million for the three months ended September 30, 2015, an increase of \$0.4 million, or 8.9%, compared to the prior year quarter. The increase in consolidated gross profit is primarily the result of a greater volume of cameras sold in our Diagnostic Imaging segment during the three months ended September 30, 2015. Diagnostic Services gross profit increased slightly for the three months ended September 30, 2015 compared to the prior year quarter, driven by increased revenue, driven in part by the MD Office acquisition, partially offset by a decrease in the average mobile imaging rate per day. Consolidated gross profit as a percentage of revenue decreased to 30.3% for the three months ended September 30, 2015,

from 31.8% for the prior year quarter, driven by unfavorability in both our Diagnostic Services and Diagnostic Imaging businesses, with the majority of the decrease attributable to decreases in the average mobile imaging rate per day and ancillary revenue from short-term equipment rentals within Diagnostic Services.

Diagnostic Services. Cost of Diagnostic Services revenue primarily consists of labor, radiopharmaceuticals, equipment depreciation, and other costs associated with providing our services. Cost of Diagnostic Services revenue was \$9.2 million for the three months ended September 30, 2015, an increase of \$1.1 million, or 14.1%, compared to the prior year quarter. The increase in cost of Diagnostic Services revenue for the three months ended September 30, 2015 as compared to the prior year quarter, is primarily a result of an increased amount of imaging days provided, driven in part by the MD Office acquisition. Diagnostic Services gross profit was \$2.8 million for both the three months ended September 30, 2015 and 2014. Diagnostic Services gross profit as a percentage of Diagnostic Services revenue decreased to 23.2% for the three months ended September 30, 2015 from 25.5% for the prior year quarter primarily due to a decrease in the average mobile imaging rate per day with the associated service costs remaining relatively consistent, as well as decreased profit from short-term equipment rentals and ancillary services.

Diagnostic Imaging. Cost of Diagnostic Imaging revenue primarily consists of materials, labor, and overhead costs associated with the manufacturing, warranty, and service contracts associated with our products. Cost of Diagnostic Imaging revenue was \$1.9 million for the three months ended September 30, 2015, an increase of \$0.5 million, or 31.9%, compared to the prior year quarter, which is primarily the result of higher camera unit sales, partially offset by a \$0.1 million increase in the release of excess inventory reserves due to the sale of previously reserved inventory in the three months ended September 30, 2015 compared to the prior year quarter. At the current expected level of camera sales, we expect to have further sales of previously reserved inventory during the remainder of 2015 and a portion of 2016, and do not anticipate significant further reserve releases thereafter. Diagnostic Imaging gross profit was \$2.0 million for the three months ended September 30, 2015, an increase of \$0.4 million, or 22.4%, compared to the prior year quarter as a result of a greater volume of camera sales, as well as the release of excess inventory reserves due to the sale of previously reserved inventory. Diagnostic Imaging gross profit as a percentage of Diagnostic Imaging revenue was 52.1% for the three months ended September 30, 2015, compared to 54.0% for the prior year quarter.

Operating Expenses

Marketing and Sales. Marketing and sales expenses consist primarily of salaries, commissions, bonuses, recruiting costs, travel, marketing and collateral materials, and trade show costs. Marketing and sales expenses were \$1.2 million for the three months ended September 30, 2015, an increase of \$0.1 million, or 4.8%, compared to the prior year quarter, primarily as a result of an increased investment in marketing mostly offset by decreased commissions and variable compensation.

General and Administrative. General and administrative expenses consist primarily of salaries and other related costs for accounting, human resources, information technology, executive personnel, legal related costs, professional fees, outside services, insurance, and costs related to our board of directors. General and administrative expenses were \$2.5 million for the three months ended September 30, 2015, an increase of \$0.5 million, or 22.5%, compared to the prior year quarter primarily as a result of \$0.4 million of legal and professional services costs related to the anticipated DMS Health acquisition.

Restructuring. On January 27, 2014, we announced a plan to exit our 47,000 square foot former headquarters facility in Poway, California (the Facilities restructuring initiative). This action was undertaken as the facility had excess space and capacity given our current operating plan. We entered into a termination agreement to end the lease on the facility as of April 30, 2014. The original term of the lease would have continued through February 29, 2016.

Concurrently with the termination of the lease for the 47,000 square foot Poway, California facility, we entered into a new lease agreement on January 23, 2014 for a separate 21,300 square foot facility in Poway, California to house our Diagnostic Imaging operations. As a result of the Facilities restructuring initiative, we incurred a total of \$0.7 million of restructuring charges, all of which were incurred during the year ended December 31, 2014. No costs were incurred related to the initiative in the three months ended September 30, 2015, which represents a decrease of \$0.1 million compared to the prior year quarter.

Income Tax Benefit (Expense)

Consolidated. Income tax benefit was \$18.2 million for the three months ended September 30, 2015, an increase of \$18.2 million compared to the prior year period. As of September 30, 2015, we concluded that it was more likely than not that a portion of our deferred tax assets would be realized through future taxable income. This conclusion was based on our restructuring efforts in 2013 and 2014 and resulting sustained profitability for the second half of 2013, 2014 and the nine months ended September 30, 2015, as well as our projections of positive future earnings and other key operating factors. As of September 30, 2015, we had generated cumulative pretax income over the preceding twelve quarter period, and therefore the objective negative evidence of a history of operating losses was no longer present. Of the \$35.0 million of deferred tax assets as of September 30, 2015, available evidence supported the realization of \$18.1 million of those assets. The release of the associated valuation allowance resulted in an income tax benefit of \$18.2 million, which was recorded as a discrete item in the three months ended September 30, 2015. The release of the valuation allowance will not affect the amount of cash paid for income taxes. We will reassess the ability to realize the deferred tax assets on a quarterly basis. If it is more likely than not that we will not realize the recognized deferred tax assets, then all or a portion of the valuation allowance may need to be re-established, which

would result in a charge to tax expense. Conversely if new events indicate that it is more likely than not that we will realize additional deferred tax assets, then all or a portion of the remaining valuation allowance may be released, which would result in a tax benefit.

Comparison of the Nine Months Ended September 30, 2015 and 2014

Revenues

Consolidated. Consolidated revenue was \$45.2 million for the nine months ended September 30, 2015, an increase of \$3.8 million, or 9.1%, compared to the prior year period, primarily due to an increase in revenue associated with our Diagnostic Services business, driven by \$1.8 million of incremental revenue associated with the MD Office acquisition, which occurred on March 5, 2015, as well as \$1.2 million of incremental cardiac event monitoring revenue associated with the Telerhythmics acquisition, which occurred on March 13, 2014. Excluding the impact of acquisitions, revenue in the Diagnostic Services business increased slightly compared to the prior year period driven by a greater number of imaging days provided, offset partially by a decrease in the average mobile imaging rate per day and a decrease in ancillary revenue from short-term equipment rentals. In addition, Diagnostic Imaging revenue for the nine months ended September 30, 2015 increased \$0.8 million compared to the prior year period, due to an increase in the number of cameras sold, as well as a more favorable product mix sold during the nine months ended September 30, 2015 as compared to the prior year period which led to a higher blended average selling price per camera period over period, offset partially by attrition in the number of camera maintenance contracts. Diagnostic Services revenue accounted for 76.7% of total revenues for the nine months ended September 30, 2015, compared to 76.5% for the prior year period.

Cost of Revenue and Gross Profit

Consolidated. Consolidated gross profit was \$13.2 million for the nine months ended September 30, 2015, an increase of \$0.9 million, or 7.0%, compared to the prior year period. The increase in consolidated gross profit is primarily the result of increased revenue and improved gross profit as a percentage of revenue in our Diagnostic Imaging segment. Our Diagnostic Imaging segment benefited from a more favorable mix of cameras sold during the nine months ended September 30, 2015 compared to the prior year period, as well as a release of excess inventory reserves due to the sale of previously reserved inventory and reduced manufacturing and overhead costs. Diagnostic Services gross profit decreased for the nine months ended September 30, 2015 compared to the prior year period, driven by a decrease in gross profit as a percentage of revenue, offset partially by increased revenue. Consolidated gross profit as a percentage of revenue decreased to 29.2% for the nine months ended September 30, 2015 from 29.8% for the prior year period, driven by unfavorability in our Diagnostic Services business partially offset by favorability in our Diagnostic Imaging business.

Diagnostic Services. Cost of Diagnostic Services revenue was \$26.9 million for the nine months ended September 30, 2015, an increase of \$3.1 million, or 13.1%, compared to the prior year period. The increase in cost of Diagnostic Services revenue is primarily due to provision of incremental cardiac event monitoring services associated with the Telerhythmics acquisition, and an increased amount of imaging days provided, driven in part by the MD Office acquisition. Diagnostic Services gross profit was \$7.8 million for the nine months ended September 30, 2015, a decrease of \$0.1 million, or 1.4%, compared to the prior year period, primarily as a result of decreased gross profit as a percentage of revenue offset partially by increased revenue volume. Diagnostic Services gross profit as a percentage of Diagnostic Services revenue decreased to 22.5% for the nine months ended September 30, 2015, from 25.0% for the prior year period due to a decrease in the average mobile imaging rate per day with the associated service costs remaining relatively consistent, as well as decreased profit from short-term equipment rentals and ancillary services.

Diagnostic Imaging. Cost of Diagnostic Imaging revenue was \$5.1 million for the nine months ended September 30, 2015, a decrease of \$0.2 million, or 3.7%, compared to the prior year period, primarily as a result of a \$0.3 million increase in release of excess inventory reserves due to the sale of previously reserved inventory in the nine months ended September 30, 2015 compared to the prior year period and a more favorable mix of cameras sold. Diagnostic Imaging gross profit was \$5.4 million for the nine months ended September 30, 2015, an increase of \$1.0 million, or 21.9%, compared to the prior year period primarily as a result of a greater volume and more favorable mix of camera sales, as well as the release of excess inventory reserves due to the sale of previously reserved inventory. Diagnostic Imaging gross profit as a percentage of Diagnostic Imaging revenue was 51.4% for the nine months ended

September 30, 2015, compared to 45.6% for the prior year period primarily due to a more favorable mix of camera sales and the release of excess inventory reserves related to the sale of previously reserved inventory.

Operating Expenses

Marketing and Sales. Marketing and sales expenses were \$3.7 million for the nine months ended September 30, 2015, an increase of \$0.2 million, or 5.5%, compared to the prior year period, primarily as a result of increased investment in marketing and sales resources associated with the Telerhythmics business, partially offset by decreased commissions and variable compensation.

General and Administrative. General and administrative expenses were \$6.9 million for the nine months ended September 30, 2015, an increase of \$0.6 million, or 10.3%, compared to the prior year period, primarily as a result of increased costs related to

the administration of the Telerhythmics business and \$0.7 million of legal and professional services costs related to the contemplated DMS Health acquisition, partially offset by decreased variable compensation.

Restructuring. On January 27, 2014, we announced a plan to exit our 47,000 square foot former headquarters facility in Poway, California (the Facilities restructuring initiative). We entered into a termination agreement to end the lease on the facility as of April 30, 2014. The original term of the lease would have continued through February 29, 2016. Concurrently with the termination of the lease for the 47,000 square foot Poway, California facility, we entered into a new lease agreement on January 23, 2014 for a separate 21,300 square foot facility in Poway, California to house our Diagnostic Imaging operations. As a result of the Facilities restructuring initiative, we incurred a total of \$0.7 million of restructuring charges, all of which were incurred during the year ended December 31, 2014. No costs were incurred related to the initiative in the nine months ended September 30, 2015, which represents a decrease of \$0.7 million compared to the prior year period.

Income Tax Benefit (Expense)

Consolidated. Income tax benefit was \$18.7 million for the nine months ended September 30, 2015, an increase of \$18.7 million compared to the prior year period. As of September 30, 2015, we concluded that it was more likely than not that a portion of our deferred tax assets would be realized through future taxable income. This conclusion was based on our restructuring efforts in 2013 and 2014 and resulting sustained profitability for the second half of 2013, 2014 and the nine months ended September 30, 2015, as well as our projections of positive future earnings and other key operating factors. As of September 30, 2015, we had generated cumulative pretax income over the preceding twelve quarter period, and therefore the objective negative evidence of a history of operating losses was no longer present. Of the \$35.0 million of deferred tax assets as of September 30, 2015, available evidence supported the realization of \$18.1 million of those assets. The release of the associated valuation allowance resulted in an income tax benefit of \$18.2 million, which was recorded as a discrete item in the three months ended September 30, 2015. The release of the valuation allowance will not affect the amount of cash paid for income taxes.

Further, during the nine months ended September 30, 2015, we recorded an income tax benefit of approximately \$0.5 million related to the release of valuation allowance associated with the acquisition of MD Office. The valuation allowance release occurred when we recorded an increase to our deferred tax liability balance as a result of book and tax basis differences in acquired fixed, intangible and other assets of MD Office.

Liquidity and Capital Resources

We generated \$3.0 million of positive cash flow from operations during the nine months ended September 30, 2015, and expect to continue to generate positive cash flow from operations on an annual basis in the future. Cash flows from operations primarily represent inflows from net income (adjusted for depreciation, amortization, and other non-cash items), as well as the net effect of changes in working capital. Cash flows from investing activities primarily represent our investment in capital equipment required to grow our business, as well as acquisition and divestiture activity. Cash flows from financing activities primarily represent outflows related to dividend payments and share repurchases, offset by the receipt of cash related to the exercise of stock options.

Our principal sources of liquidity are our existing cash and cash equivalents, short-term investments, and cash generated from operations. As of September 30, 2015, we had cash, cash equivalents, and securities available-for-sale of \$19.9 million. We generally invest our cash reserves in money market funds, U.S. treasury, and corporate debt securities. In regards to additional sources of financing, we currently have available a shelf registration statement that provides us with increased capital flexibility to pursue corporate objectives by allowing us to offer and sell up to \$20.0 million of securities. Further, in connection with the contemplated acquisition of DMS Health, we entered into a commitment letter with Wells Fargo pursuant to which Wells Fargo committed, on the terms and conditions set forth in the Commitment Letter (the Commitments), to provide the Company with a senior secured credit facility in the aggregate amount of \$40 million (the Credit Facility). The Commitments under the Commitment Letter are subject to various conditions, including consummation of the contemplated acquisition of DMS Health. In the event the initial funding under the Credit Facility does not occur on or prior to January 15, 2016, then Wells Fargo's commitment to provide the Credit Facility will automatically expire on such date.

We require capital principally for capital expenditures, acquisition activity, dividend payments, and to finance accounts receivable and inventory. Our working capital requirements vary from period to period depending on

inventory requirements, the timing of deliveries, and the payment cycles of our customers. Our capital expenditures consist primarily of nuclear cameras, cardiac monitoring devices, ultrasound machines, vans, and computer hardware and software. Based upon our current level of expenditures, we believe our current working capital, together with cash flows from operating activities, will be more than adequate to meet our anticipated cash requirements for at least the next 12 months.

Cash Flows

The following table shows cash flow information for the nine months ended September 30, 2015 and 2014:

(in thousands)	Nine Months Ended September 30,	
	2015	2014
Net cash provided by operating activities	\$2,965	\$2,979
Net cash used in investing activities	(291) (6,035
Net cash used in financing activities	(2,830) (2,895

Operating Activities

Net cash provided by operating activities remained consistent for the nine months ended September 30, 2015 compared to the prior year period. Cash inflows from net income (adjusted for depreciation, amortization, and other non-cash items) increased for the nine months ended September 30, 2015 compared to the prior year period, but were offset by unfavorable changes in operating assets and liabilities primarily related to increases in accounts receivable and inventory.

Investing Activities

Net cash used in investing activities decreased \$5.7 million for the nine months ended September 30, 2015 compared to the prior year period. This decrease was primarily attributable to increased cash provided by maturities of available-for-sale securities in the nine months ended September 30, 2015, compared to the outlay of cash to acquire Telerhythmics and purchases of available-for-sale securities in the nine months ended September 30, 2014. See Note 3 to the unaudited condensed consolidated financial statements for further information related to the acquisition of Telerhythmics.

Financing Activities

Net cash used in financing activities decreased by \$0.1 million for the nine months ended September 30, 2015 compared to the prior year period. This decrease was primarily attributable to increased proceeds received from stock option exercises during the nine months ended September 30, 2015.

Off-Balance Sheet Arrangements

As part of our ongoing business, we do not participate in transactions that generate relationships with unconsolidated entities or financial partnerships, such as entities often referred to as structured finance or special purpose entities, or SPEs, which would have been established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes. As of September 30, 2015, we were not involved in any unconsolidated SPE transactions.

Contractual Obligations

There have been no material changes outside of the ordinary course of business in our outstanding contractual obligations from those disclosed within "Management's Discussion and Analysis of Financial Condition and Results of Operations," as contained in our Annual Report on Form 10-K filed with the SEC on March 6, 2015.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Our exposure to market risk due to changes in interest rates relates primarily to the increase or decrease in the value of debt securities in our investment portfolio. Our risk associated with fluctuating interest rates is limited to our investments in interest rate sensitive financial instruments. Under our current policies, we do not use interest rate derivative instruments to manage exposure to interest rate changes. We attempt to increase the safety and preservation of our invested principal funds by limiting default risk, market risk, and reinvestment risk. We mitigate default risk by investing in investment grade securities. A 100 basis point adverse move in interest rates along the entire interest rate yield curve would not materially affect the fair value of our interest sensitive financial instruments. Changes in interest rates over time will increase or decrease our interest income.

ITEM 4. CONTROLS AND PROCEDURES

Disclosure Controls and Procedures

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our Securities and Exchange Commission Act of 1934 reports is recorded, processed, summarized, and reported within the time periods specified in the Securities and Exchange Commission's rules and forms, and that such information is accumulated and communicated to our management, including our chief executive officer and chief financial officer, as appropriate, to allow for timely decisions regarding required disclosure. In designing and

evaluating the disclosure controls and procedures, we recognize that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

As required by Securities and Exchange Commission Rule 13a-15(e) and 15d-15(e), we carried out an evaluation, under the supervision and with the participation of our management, including our chief executive officer and chief financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this report. Based on the foregoing, our chief executive officer and chief financial officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level.

Our disclosure controls and procedures are designed to provide reasonable assurance of achieving their objectives as specified above. Management does not expect, however, that our disclosure controls and procedures will prevent or detect all errors and fraud. Any control system, no matter how well designed and operated, is based upon certain assumptions and can provide only reasonable, not absolute, assurance that its objectives will be met. Further, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, within the Company have been detected.

Changes in Internal Control over Financial Reporting

There has been no change in our internal controls over financial reporting during our most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal controls over financial reporting.

PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

See Note 10 to the unaudited Condensed Consolidated Financial Statements for a summary of legal proceedings.

ITEM 1A. RISK FACTORS

In evaluating us and our common stock, we urge you to carefully consider the risks and other information in this Quarterly Report on Form 10-Q, as well as the risk factors disclosed in Item 1A to Part I of our Annual Report on Form 10-K for the fiscal year ended December 31, 2014, which we filed with the SEC on March 6, 2015. Beyond what is described below, the risks and uncertainties described in “Item 1A – Risk Factors” of our Annual Report on Form 10-K have not materially changed. Any of the risks discussed in this Quarterly Report on Form 10-Q or any of the risks disclosed in Item 1A to Part I of our Annual Report on Form 10-K for the fiscal year ended December 31, 2014, as well as additional risks and uncertainties not currently known to us or that we currently deem immaterial, could materially and adversely affect our results of operations or financial condition.

Our pending acquisition of DMS Health and related financing with Wells Fargo may not be consummated, and if consummated we may not realize the anticipated benefits from the Transaction.

We have spent time and money on the pending acquisition of DMS Health and arranging for related financing with Wells Fargo, but we may not be able to consummate the acquisition or the related financing because of a failure to obtain the necessary consents and approvals or to satisfy other conditions to closing.

If we do consummate the Transaction, we will face certain challenges as we integrate DMS Health operational and administrative systems into our business. Acquisitions include many complexities, which can include, but are not limited to, risks associated with the acquired business' past activities, loss of customers, regulatory changes that are not anticipated, difficulties in integrating personnel and human resource programs, integrating ERP systems and other infrastructures, and general under performance of the acquired business under Digirad control versus the prior owners. In addition, debt covenants under the related Wells Fargo credit facility may result in reduced operational flexibility for the Company.

There is no guarantee that the acquisition of DMS Health will increase the profitability and cash flow of Digirad, and our efforts could cause unforeseen complexities and additional cash outflows, including financial losses. As a result, the realization of anticipated synergies or benefits of the acquisition may be delayed or substantially reduced.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5. OTHER INFORMATION

None.

ITEM 6. EXHIBITS

Exhibit Number	Description
2.1	Membership Interest Purchase Agreement, dated March 13, 2014 by and among Digirad Imaging Solutions, Inc., Digirad Corporation, the Sellers party thereto, and TD Properties, LLC in its capacity as Seller Representative (Incorporated by reference to the exhibits to the Company's report on Form 8-K filed with the Commission on March 14, 2014.)
2.2	Agreement of Merger and Plan of Reorganization, dated March 5, 2015 by and between Digirad Corporation, Maleah Incorporated, MD Office Solutions, and the Stockholders party thereto (Incorporated by reference to the exhibits to the Company's report on Form 8-K filed with the Commission on March 6, 2015). Schedules and exhibits have been omitted pursuant to Item 601(b)(2) of Regulation S-K. The Company hereby agrees to furnish supplementary copies of any of the omitted schedules or exhibits upon request by the Securities and Exchange Commission.
3.1	Restated Certificate of Incorporation of Digirad Corporation (Incorporated by reference to the exhibits to the Company's report on Form 8-K originally filed with the Commission on May 3, 2006, as amended thereafter).
3.2	Certificate of Designation of Rights, Preferences and Privileges of Series B Participating Preferred Stock (Incorporated by reference to the exhibits to the Company's report on Form 8-K filed with the Commission on May 24, 2013).
3.3	Certificate of Amendment of the Restated Certificate of Incorporation of Digirad Corporation (Incorporated by reference to the exhibits to the Company's report on Form 8-K filed with the Commission on May 5, 2015).
31.1*	Certification of the Principal Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) promulgated pursuant to the Securities Exchange Act of 1934, as amended.
31.2*	Certification of the Principal Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a) promulgated pursuant to the Securities Exchange Act of 1934, as amended.
32.1**	Certification of the Principal Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2**	Certification of the Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS*	XBRL Instance Document
101.SCH*	XBRL Taxonomy Extension Schema
101.CAL*	XBRL Taxonomy Extension Calculation Linkbase
101.LAB*	XBRL Taxonomy Extension Labels Linkbase
101.PRE*	XBRL Taxonomy Extension Presentation Linkbase
101.DEF*	XBRL Taxonomy Extension Definition Linkbase

*Filed herewith.

This certification is being furnished solely to accompany this quarterly report pursuant to 18 U.S.C. § 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of Digirad Corporation, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

SIGNATURES

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

DIGIRAD CORPORATION

Date: November 2, 2015

By: /s/ MATTHEW G. MOLCHAN
Matthew G. Molchan
President and Chief Executive Officer
(Principal Executive Officer)

Date: November 2, 2015

By: /s/ JEFFRY R. KEYES
Jeffry R. Keyes
Chief Financial Officer
(Principal Financial and Accounting Officer)